24 Mar 2018 Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes
24 Mar 2018 Sandoz receives positive CHMP opinion for proposed biosimilar infliximab
24 Mar 2018 Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer
22 Mar 2018 AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer
22 Mar 2018 argenx announces expansion of its pipeline with addition of complement-targeted ARGX-117 for treatment of severe autoimmune diseases
22 Mar 2018 FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
21 Mar 2018 Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
21 Mar 2018 Surface Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of SRF231
21 Mar 2018 Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) in Combination with Chemotherapy for Adults with Previously Untreated Stage III or IV Classical Hodgkin Lymphoma
20 Mar 2018 Phase III IMpower131 Study Showed Genentech’s TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin and ABRAXANE) Reduced The Risk of Disease Worsening or Death in the Initial Treatment of People With a Type of Advanced Squamous Lung Cancer
19 Mar 2018 EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial
19 Mar 2018 Elthera Announces Positive Preclinical Proof of Concept (POC) Studies and Start of New Financing Round
17 Mar 2018 FDA Approves Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
16 Mar 2018 First patient with acquired fibrinogen deficiency treated in clinical phase III study of Biotest AG
15 Mar 2018 Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
15 Mar 2018 Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia
13 Mar 2018 Actinium Announces FDA Clearance of IND For Phase 1 trial of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
13 Mar 2018 Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis
13 Mar 2018 FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer
12 Mar 2018 All time high of biologics sales in 2017 driven by cancer and innovative anti-inflammatory antibodies
12 Mar 2018 Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need
12 Mar 2018 Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
07 Mar 2018 Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma
07 Mar 2018 Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer
07 Mar 2018 Bioverativ Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing